ImExHS (IME) AGM 2026 presentation summary
Event summary combining transcript, slides, and related documents.
AGM 2026 presentation summary
20 May, 2026Leadership and governance
Board includes experienced non-executive directors and a CEO with medical and operational expertise.
Management team covers finance, operations, sales, and medical leadership roles.
Business overview and strategy
Operates two core businesses: medical imaging software and radiology services, primarily in Colombia.
Focus on democratising access to medical imaging expertise.
Strategic emphasis on automation, AI-driven workflows, and selective portfolio management.
Operational and financial performance
FY25 revenue reached $29.0m, up 10% year-over-year, with ARR at $34.8m, up 16%.
Underlying EBITDA for FY25 was $1.6m, at the top end of guidance.
Cash increased to $3.3m and debt reduced to $0.5m by year-end.
Q1 FY26 revenue grew 13% to $7.9m, with EBITDA at $0.8m.
Latest events from ImExHS
- Revenue up 34% to $26.5m, ARR at $30m, and EBITDA positive amid strong contract wins.IME
H2 202429 May 2026 - Revenue up 57% and ARR up 21% year-over-year, with margin gains targeted but cash risks persist.IME
H1 202429 May 2026 - ARR up 11% to $32.8m, revenue up 4%, with FY25 guidance positive despite impairment.IME
H1 202529 May 2026 - Revenue up 10%, EBITDA at $1.6m, ARR up 16%, and positive cash flow with reduced debt.IME
H2 202529 May 2026 - Strong Q1 FY26 growth driven by AI-native platform and robust software/services performance.IME
Q1 2026 TU30 Apr 2026 - Q3 FY25 delivered 9% revenue and 24% ARR growth, margin gains, and reaffirmed FY25 guidance.IME
Q3 2025 TU13 Nov 2025 - Robust financial growth and strategic software rollout drive positive 2025 outlook.IME
AGM 20256 Jun 2025